Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

GLP-1 agonist

  • Home
  • GLP-1 agonist
Assessing the Impact of Exenatide Infusion During Cardiopulmonary Bypass in CABG and Aortic Valve Replacement Surgery
Posted inCardiology news Specialties

Assessing the Impact of Exenatide Infusion During Cardiopulmonary Bypass in CABG and Aortic Valve Replacement Surgery

Posted by MedXY By MedXY 08/17/2025
A randomized clinical trial found that exenatide infusion during and after cardiopulmonary bypass did not reduce death or major organ failure in low-risk patients undergoing coronary artery bypass grafting or aortic valve replacement.
Read More
Amycretin: A Novel Unimolecular GLP-1 and Amylin Receptor Agonist for Obesity – Early-Phase Clinical Insights and Broader GLP-1 Drug Development Perspective
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Amycretin: A Novel Unimolecular GLP-1 and Amylin Receptor Agonist for Obesity – Early-Phase Clinical Insights and Broader GLP-1 Drug Development Perspective

Posted by MedXY By MedXY 08/02/2025
Amycretin, a new unimolecular GLP-1 and amylin agonist, demonstrated significant weight loss and acceptable tolerability in a phase 1b/2a study, underscoring its potential as an anti-obesity therapy.
Read More
  • Persistent Elevated Risk of Severe COVID-19 Outcomes in Pregnant and Postpartum Individuals Beyond the Pandemic Emergency
  • Unraveling Hepatitis B-Induced Liver Fibrosis: The Critical Role of Pyruvate, PPARα, and Reactive Oxygen Species
  • Unveiling the Role of IL-10-Neutralising Autoantibodies in Pediatric-Onset Inflammatory Bowel Disease: Prevalence, Persistence, and Clinical Implications
  • Decoding Microbial Shifts in Postoperative Crohn’s Disease: Insights into Recurrence Dynamics
  • Perfusion Imaging’s Role in Endovascular Therapy Outcomes for Posterior Cerebral Artery Stroke
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in